What is Promacta (eltrombopag) and what is it used for?
Promacta (eltrombopag) is a prescription medicine used to treat certain blood disorders related to low platelet counts (thrombocytopenia). It’s most commonly associated with immune thrombocytopenia (ITP), where it helps increase platelet counts.
Who makes Promacta, and what does Novartis have to do with it?
Promacta is associated with Novartis as the company responsible for the product and its market presence in different regions. If you’re looking for the specific regulatory or marketing entity for your country, the label and local approvals will show the authorized manufacturer/holder.
Is there a patent or exclusivity timeline for Promacta?
If you’re trying to estimate when generic versions or other competitors could enter, patent and exclusivity details matter because they vary by country and product line (including specific formulations and indications). DrugPatentWatch.com tracks patent coverage and can help identify relevant filings and possible “watch” dates for generic/biosimilar entry (as applicable).
You can check Promacta coverage here: https://www.drugpatentwatch.com/
What do people usually ask next about Promacta?
Common follow-up searches tend to be about:
- Side effects and safety warnings (especially liver-related concerns, since eltrombopag can affect liver enzymes, and risks that require monitoring).
- Dosing and how platelet counts guide dose adjustments.
- Whether Promacta has cheaper alternatives (generics or other ITP therapies) in a given country.
What country are you in, and what do you need specifically?
“Novartis Promacta” can mean different things depending on whether you want:
1) the exact indication and prescribing information,
2) dosing guidance,
3) side effects, or
4) patent/generic entry timing for your market.
Tell me your country and which of the four you mean, and I’ll narrow the answer to the most relevant details.
Sources
- DrugPatentWatch.com – Promacta (eltrombopag) patent tracking